NEC infant formula lawsuit MDL 3026: where the cow's milk formula litigation actually stands

The NEC infant formula litigation involves one of the most heartbreaking case theories in modern mass tort practice. MDL 3026 (In re: Abbott Laboratories, et al., Preterm Infant Nutrition Products Liability Litigation), centralized in the U.S. District Court for the Northern District of Illinois before Judge Rebecca R. Pallmeyer, consolidates approximately 797 federal cases as of May 2026 alleging that cow's milk-based premature infant formulas manufactured by Abbott Laboratories (Similac) and Mead Johnson & Company (Enfamil) cause necrotizing enterocolitis (NEC) in premature infants. NEC is a devastating intestinal disease that destroys parts of the bowel, often requiring surgical removal of damaged intestine, with high mortality rates and permanent disability for survivors.

The procedural posture has been complex. Federal MDL bellwether trials produced setbacks for plaintiffs in 2025-2026. The first three bellwether cases against Abbott Laboratories were dismissed on summary judgment after Judge Pallmeyer found that plaintiffs hadn't adequately established the existence of feasible alternatives to cow's milk-based formulas at scale during the relevant time periods. The summary judgment ruling effectively required plaintiffs to demonstrate not just that cow's milk formulas caused NEC, but that human milk-based alternatives could have replaced them in the NICU setting where premature infants are fed. The ruling has been controversial — plaintiffs argue donor human milk was widely available, while defendants argue the scale wasn't sufficient for routine NICU use.

The state court track has been substantially more favorable to plaintiffs. Major plaintiff verdicts include the March 2024 $60 million Illinois state court verdict against Mead Johnson (Enfamil), the July 2024 $495 million Missouri state court verdict against Abbott (Similac), and the April 2026 $70 million Chicago jury verdict against Abbott (Similac Special Care 24) for four mothers whose premature babies developed NEC. Combined plaintiff verdicts now exceed $625 million. The contrast between the federal MDL summary judgment dismissals and the substantial state court plaintiff verdicts has substantially affected litigation dynamics — plaintiffs' counsel have increasingly directed cases to state courts where the procedural framework has been more receptive.

The first federal bellwether trial against Mead Johnson is scheduled for July 6, 2026 in Inman v. Mead Johnson, involving the death of Alexis Inman's son Daniel days after birth from NEC allegedly caused by Enfamil. The trial will be followed by an Abbott (Similac) bellwether on August 10, 2026. Two additional bellwethers are scheduled for August 3 and November 2, 2026, with another set for February 1, 2027. These bellwether outcomes will substantially affect whether the federal MDL framework remains viable for plaintiffs or whether state court filings will continue to dominate the litigation.

This is the science behind the NEC-formula connection, the procedural history of MDL 3026 and parallel state court litigation, the eligibility framework for filing claims, the strategic considerations for current and prospective plaintiffs, and what the upcoming bellwether trials mean for the litigation's future.

What NEC is and the case theory

Necrotizing enterocolitis is a devastating gastrointestinal disease primarily affecting premature infants:

The disease. NEC causes inflammation and bacterial invasion of the intestinal wall, which can rapidly progress to tissue death (necrosis). The damaged intestinal tissue can perforate, allowing bacteria to enter the bloodstream and cause sepsis. NEC typically develops in the first weeks of life in premature infants, often after the introduction of enteral feeding.

Population affected. NEC primarily affects very premature infants — those born before 32 weeks gestation and especially those weighing less than 1,500 grams (very low birth weight) or less than 1,000 grams (extremely low birth weight). The disease affects approximately 5-10% of very low birth weight infants in the U.S.

Mortality and morbidity. NEC has a mortality rate of 20-40% depending on severity. Survivors often experience significant long-term complications including short bowel syndrome (after surgical removal of damaged intestine), developmental delays, cognitive impairment, and persistent gastrointestinal problems.

Treatment. Treatment involves intensive medical care including bowel rest, antibiotics, and in severe cases surgical removal of necrotic intestine. Surgery can result in permanent intestinal damage requiring long-term parenteral nutrition and other interventions.

The case theory in MDL 3026:

Cow's milk-based formula causation. Plaintiffs allege that cow's milk-based premature infant formulas (Similac Special Care, Similac Special Care 24, Enfamil Premature, Enfamil Premature High Protein, similar specialized premature formulas) significantly increase the risk of NEC compared to human milk-based feeding.

Scientific basis. Multiple studies have shown that premature infants fed exclusively or predominantly with human milk (mother's milk or donor human milk) have substantially lower rates of NEC than infants fed cow's milk-based formula. Studies suggest NEC risk is reduced by 50-77% with human milk feeding.

Mechanism theory. The protective effect of human milk is attributed to multiple components: bioactive compounds that promote intestinal development, immunological factors that protect against infection, growth factors that support intestinal mucosal integrity, and the absence of cow's milk proteins that may trigger inflammatory responses in immature intestines.

Failure to warn theory. Plaintiffs allege that Abbott and Mead Johnson failed to warn:

Parents about the increased NEC risk from cow's milk-based formulas
Medical professionals about the disparity in NEC rates
The general public about the safer alternatives available

Internal corporate knowledge. Discovery has produced internal documents from Abbott and Mead Johnson showing awareness of NEC studies and the protective effect of human milk for years before the litigation. Plaintiffs argue the companies should have updated labeling and informed consent practices based on this evidence.

The federal MDL track

MDL 3026 was consolidated in April 2022:

Centralized in N.D. Illinois. Judge Rebecca R. Pallmeyer was assigned to oversee the litigation. The court has been managing the substantial pre-trial work for the consolidated cases.

Case count. Approximately 797 cases pending as of May 2026, with roughly 950 total filings over time. The case count has remained relatively stable as some plaintiffs have moved cases to state court where the framework has been more favorable.

Bellwether selection. Judge Pallmeyer designated four bellwether cases:

Two cases naming both Abbott and Mead Johnson
One case naming only Mead Johnson (Enfamil)
One case naming only Abbott (Similac)
Three of the four are wrongful death cases (infant died from NEC); the fourth involves an infant who survived NEC but with severe complications.

Summary judgment dismissals. The first three federal bellwether cases against Abbott were dismissed on summary judgment. Judge Pallmeyer found that plaintiffs had failed to adequately demonstrate that feasible alternatives to cow's milk-based formulas existed at scale during the relevant time periods. The ruling was significant because it effectively created an additional element of proof for plaintiffs.

The "feasible alternative" issue. The summary judgment ruling has been controversial. Plaintiffs argued:

Donor human milk was available through milk banks
The federal government had supported milk bank expansion
Some NICUs were successfully using donor human milk during the relevant periods

Defendants argued:

The scale of donor human milk wasn't sufficient for routine NICU use
Donor human milk has its own concerns (contamination, supply chain)
The medical standard of care in the relevant period was cow's milk formulas

The court sided with defendants on the summary judgment ruling, but the framework's application to other cases (particularly cases involving more recent time periods when human milk was more available) remains uncertain.

Inman v. Mead Johnson — first remaining bellwether. Originally scheduled for February 2, 2026, the trial was rescheduled to July 6, 2026 following pretrial rulings. The case involves the death of Alexis Inman's son Daniel within days of birth from NEC allegedly caused by Enfamil. This will be the first MDL trial against Mead Johnson specifically.

Subsequent bellwether schedule. Abbott (Similac) bellwether August 10, 2026. Additional bellwethers August 3 and November 2, 2026, with another February 1, 2027.

Expert testimony. Judge Pallmeyer has issued various rulings on expert testimony admissibility. The court struck down one of defendants' proposed experts who challenged the causation link, citing inaccurate figures and unexplained criteria. The ruling supports plaintiffs' expert testimony framework for future bellwethers.

The state court track

State court litigation has been substantially more favorable to plaintiffs:

March 2024: Illinois state court — $60 million. First substantial NEC plaintiff verdict. The Cook County, Illinois jury found Mead Johnson liable for the death of a premature infant who developed NEC after consuming Enfamil. The verdict included compensatory and punitive damages.

July 2024: Missouri state court — $495 million. The largest NEC verdict to date. A Madison County, Illinois (actually a Missouri case) jury found Abbott Laboratories liable for a Similac-linked NEC injury. The verdict reflected the strength of state court juries' willingness to find for plaintiffs in NEC cases.

October 2024: St. Louis — Defense verdict. A St. Louis jury sided with both Abbott and Mead Johnson in one case, breaking the trend of plaintiff verdicts. The defense win provided some balance to the litigation landscape.

March 2025: Missouri defense verdict overturned. A judge overturned the October 2024 defense verdict and ordered retrial after findings of defense counsel misconduct. The retrial framework continues.

April 10, 2026: Chicago, $70 million. The most recent major NEC verdict. A Chicago jury ordered Abbott Laboratories to pay $70 million to four mothers whose premature babies developed NEC after consuming Similac Special Care 24 formula. The award included $53 million in actual damages and $17 million in punitive damages. The jury found Abbott failed to warn about the NEC risk.

Combined plaintiff verdicts. Over $625 million in NEC plaintiff verdicts across state courts as of mid-2026. The substantial verdicts have substantially affected litigation dynamics.

Why state courts favor plaintiffs. Several factors contribute to plaintiff success in state courts:

State court pleading standards are sometimes more permissive
State juries have shown sympathy for the human impact of NEC
State court summary judgment standards differ from federal practice
State courts haven't applied the "feasible alternative" requirement consistently

The state court success has drawn additional plaintiffs to state court filings, particularly in jurisdictions with favorable case law and jury pools.

The conditions alleged

NEC litigation involves a range of injury severities:

Death from NEC. The most severe outcome. Many premature infants don't survive NEC. Wrongful death claims by parents on behalf of estates of deceased infants are common in the litigation.

Severe NEC requiring surgical intervention. Survivors who required bowel resection surgery to remove necrotic intestine. Long-term consequences include short bowel syndrome.

Short bowel syndrome. Permanent consequence of substantial bowel resection. The reduced intestinal length impairs nutrient absorption, often requiring long-term parenteral nutrition (IV feeding), dietary restrictions, and various complications.

Developmental delays. NEC and the associated medical treatments can produce neurodevelopmental complications. Severe NEC has been associated with cognitive impairment, motor delays, and similar developmental issues.

Chronic gastrointestinal complications. Survivors often have chronic gastrointestinal problems including strictures, dysmotility, and nutritional issues.

Other neonatal complications. Premature infants with NEC often experience multiple other complications including sepsis, respiratory problems, and various medical complications that compound the NEC injury.

Long-term medical care needs. Survivors typically require ongoing medical care for years or for life depending on injury severity. The medical care costs can be substantial.

The case values reflect the severity of these injuries. Cases involving infant death typically produce higher damages than cases involving milder NEC outcomes. The Missouri $495 million verdict and the Chicago $70 million verdict (for 4 plaintiffs) reflect the substantial damages juries have been willing to award for these injuries.

Eligibility framework

The framework for filing NEC infant formula claims:

Premature birth. The infant was born premature, typically before 37 weeks gestation, often before 34 weeks for stronger cases. The strongest cases involve very premature infants (before 32 weeks).

Low birth weight. Infants weighing less than 2,500 grams at birth, often less than 1,500 grams (very low birth weight) for stronger cases.

Cow's milk-based formula feeding. The infant was fed Similac (Abbott products) or Enfamil (Mead Johnson products) premature formulas in the NICU. Documentation through NICU feeding records, hospital records, and pharmacy records.

Specific products implicated. The major implicated products include:

Similac Special Care (Abbott)
Similac Special Care 24 (Abbott)
Similac Special Care 30 (Abbott)
Enfamil Premature (Mead Johnson)
Enfamil Premature High Protein (Mead Johnson)
Enfamil Premature with iron (Mead Johnson)

NEC diagnosis. Documented diagnosis of NEC during NICU stay. The diagnosis should be supported by:

Clinical signs of NEC
Radiologic evidence (pneumatosis intestinalis, portal venous gas, or perforation)
Surgical findings if surgical intervention occurred
Pathology if intestinal tissue was examined

Temporal connection. NEC developed after exposure to cow's milk-based formula. The strongest cases involve clear temporal sequence with formula introduction followed by NEC development.

Injury severity. Significant injury including death, surgical intervention, short bowel syndrome, or other major complications. Mild NEC cases without significant long-term consequences are weaker.

Statute of limitations compliance. State-specific limitations periods apply. Many states have specific tolling provisions for injuries to minors, allowing claims to be filed years after the injury occurred. Wrongful death cases have their own limitations frameworks.

No significant alternative causation. Cases involving strong alternative explanations for NEC (severe infections, congenital intestinal abnormalities, etc.) face more difficult causation analysis.

The strongest typical case profile:

A very premature infant (born before 32 weeks gestation) fed Similac Special Care or Enfamil Premature in the NICU, who developed severe NEC requiring surgical intervention, who either died from the disease or survived with substantial long-term complications, with comprehensive NICU and follow-up medical records documenting the entire timeline.

Settlement projections

No global settlement has been reached. Projections from plaintiffs' counsel:

Per-case ranges. Highly variable based on case specifics:

Cases involving infant death: $1 million to $5 million+ for typical cases, much higher for severe cases
Cases involving severe NEC with surgical intervention and lasting complications: $500,000 to $3 million+
Less severe cases: $100,000 to $500,000

State court influence. State court verdicts have substantially affected settlement projections. The $495 million Missouri verdict and the $70 million Chicago verdict (for 4 plaintiffs) suggest substantial per-case settlement potential.

Federal MDL uncertainty. The summary judgment dismissals in federal bellwether cases create uncertainty about federal MDL case values. The upcoming Inman bellwether (July 6, 2026) will provide additional information about federal MDL framework.

Total exposure. With ~800 federal MDL cases plus hundreds of state court cases, total exposure for Abbott and Mead Johnson is potentially in the $2-5 billion range depending on settlement framework. Both companies are major corporations with substantial financial capacity for settlement.

How NEC compares to other mass torts

The litigation has distinctive features:

Most affected population is voiceless. The plaintiffs are infants who couldn't make decisions about their feeding. The cases proceed through parents and guardians on behalf of injured infants. This contrasts with most mass torts where adult plaintiffs make their own choices about product use.

Compared to Tylenol autism MDL which was dismissed: Both involve injuries to children. Tylenol autism cases were dismissed due to causation evidence problems. NEC has stronger established science and continuing viable cases.

Compared to Talcum powder MDL 2738 with state court success: Both involve products marketed to specific populations with state court success exceeding federal MDL progress. The contrast between federal and state procedural success is similar.

Compared to Camp Lejeune water contamination: Both involve products/exposures affecting vulnerable populations. NEC operates through typical MDL framework; Camp Lejeune through specific statutory framework.

Compared to Roundup litigation which produced $11+ billion in settlements: Both involve products with substantial documented internal corporate knowledge. Roundup is procedurally further along with multiple bellwether outcomes.

Compared to Paragard IUD MDL 2974: Both have faced bellwether setbacks but with state court success in NEC's case. Paragard's defense bellwether verdict reduces leverage; NEC has the federal MDL summary judgment problem.

The broader procedural framework for mass tort settlements is detailed in our overview of how mass tort litigation works. NEC represents one of the most procedurally complex mass torts with substantial divergence between federal MDL and state court outcomes.

Strategic considerations

For parents and families of NEC-affected infants:

Consider both federal MDL and state court options. Given the procedural divergence, the strategic choice between federal MDL filing and state court filing has substantial impact on case outcomes. Experienced counsel can evaluate which framework fits the specific case better.

Engage NEC-experienced counsel. The litigation is procedurally complex and emotionally challenging. Counsel with established NEC case experience handles these cases substantially better than general personal injury attorneys.

Document the NICU timeline thoroughly. Records of:

Birth records and gestational age
NICU admission records
Feeding records (specific formulas used and timing)
NEC diagnosis records
Treatment records including any surgical interventions
Post-NICU follow-up care
Long-term medical records for survivors

Wrongful death framework for deceased infants. Estates of deceased infants pursue wrongful death claims. The framework varies by state and includes economic damages, conscious pain and suffering, and parental damages.

Coordinate with medical providers. The NICU physicians, nurses, and other providers who treated the infant are important witnesses. Their support for the case theory strengthens the case substantially.

Don't delay filing. Statutes of limitations for minor injuries are typically tolled, but the tolling has limits. Wrongful death claims have specific limitations frameworks. Early consultation preserves claim viability.

Be realistic about timeline. Federal MDL bellwethers proceeding through 2026-2027. State court cases vary by jurisdiction. Plan for 2-4 year resolution timelines for most cases.

Coordinate with insurance and Medicaid recovery. Medical bills paid by insurance or Medicaid may be subject to subrogation rights. The recovery framework requires careful coordination with healthcare payers.

Watch the July 6, 2026 Inman trial. This will be the first federal MDL bellwether against Mead Johnson and the first remaining bellwether after the Abbott summary judgment dismissals. The outcome will substantially affect federal MDL framework going forward.

Don't accept inadequate settlements. Despite uncertainty in the federal MDL, the substantial state court verdicts demonstrate the potential value of these cases. Have any settlement offer evaluated by experienced counsel before accepting.

For families of premature infants who developed NEC after cow's milk-based formula feeding, MDL 3026 and parallel state court litigation provide paths to compensation that recognize the serious harm caused by these products. The procedural complexity is substantial, with divergent outcomes between federal and state courts, but the underlying case theory is supported by strong scientific evidence and substantial state court plaintiff verdicts. The upcoming Inman bellwether trial in July 2026 will substantially affect federal MDL framework, while continuing state court litigation continues providing meaningful recovery for many plaintiffs. The work for affected families is engagement with experienced counsel, comprehensive documentation of the NICU and follow-up medical timeline, strategic decision-making about federal vs. state court filing, and patient navigation of the extended litigation timeline. For cases that proceed to favorable outcomes, the framework can produce substantial compensation that addresses the lifelong consequences of NEC for surviving infants and the catastrophic loss for families of infants who died from the disease.